TY - JOUR
T1 - PHOTODYNAMIC THERAPY with VERTEPORFIN PLUS INTRAVITREAL BEVACIZUMAB for CIRCUMSCRIBED CHOROIDAL HEMANGIOMA
T2 - 4 YEARS of FOLLOW-UP
AU - Lasave, Andres F.
AU - Serrano, Martin A.
AU - Arevalo, J. Fernando
N1 - Funding Information:
Supported in part by the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela.
Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Purpose:To report the anatomical and functional response of combined photodynamic therapy and intravitreal injection of bevacizumab in a patient with symptomatic circumscribed choroidal hemangioma.Methods:The patient received a single-session full-fluence photodynamic therapy immediately followed by an intravitreal injection of bevacizumab (1.25 mg/0.05 mL).Results:One week after combined therapy, an improvement of best-corrected visual acuity from count fingers to 20/60 and a significant decrease in subretinal fluid were noted. One month later, we observed decreased leakage on fluorescein angiography in all phases of the study. Three months after treatment, the best-corrected visual acuity improved to 20/25 and spectral domain optical coherence tomography scans showed return to normal foveal architecture with no subretinal fluid and completely flat tumor. These findings were maintained during 4 years of follow-up.Conclusion:Combination therapy was associated with a rapid and persistent resolution of subretinal fluid, improvement of best-corrected visual acuity, and visual stability at 4 years of follow-up.
AB - Purpose:To report the anatomical and functional response of combined photodynamic therapy and intravitreal injection of bevacizumab in a patient with symptomatic circumscribed choroidal hemangioma.Methods:The patient received a single-session full-fluence photodynamic therapy immediately followed by an intravitreal injection of bevacizumab (1.25 mg/0.05 mL).Results:One week after combined therapy, an improvement of best-corrected visual acuity from count fingers to 20/60 and a significant decrease in subretinal fluid were noted. One month later, we observed decreased leakage on fluorescein angiography in all phases of the study. Three months after treatment, the best-corrected visual acuity improved to 20/25 and spectral domain optical coherence tomography scans showed return to normal foveal architecture with no subretinal fluid and completely flat tumor. These findings were maintained during 4 years of follow-up.Conclusion:Combination therapy was associated with a rapid and persistent resolution of subretinal fluid, improvement of best-corrected visual acuity, and visual stability at 4 years of follow-up.
KW - bevacizumab
KW - circumscribed choroidal hemangioma
KW - intravitreal anti-vascular endothelial growth factor
KW - photodynamic therapy
UR - http://www.scopus.com/inward/record.url?scp=85075662681&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075662681&partnerID=8YFLogxK
U2 - 10.1097/ICB.0000000000000677
DO - 10.1097/ICB.0000000000000677
M3 - Article
C2 - 29176523
AN - SCOPUS:85075662681
SN - 1935-1089
VL - 14
SP - 110
EP - 115
JO - Retinal Cases and Brief Reports
JF - Retinal Cases and Brief Reports
IS - 2
ER -